Skip to content
Disclosery

Nextech Invest Ltd.

Follow

13F filer, CIK 1911010, Zurich, Switzerland

Nextech Invest Ltd. reported $294,203,998 across 13 holdings for the quarter ended 2023-06-30, in a 13F-HR filed 2023-08-14. Its ten largest share positions make up 97.8% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-23-091377

Period
2023-06-30
Reported value
$294M
Holdings
13
Top 10 weight
97.8%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ORICnew+4,285,714$33.3M
RLAYadded+323,174$4.06M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PMVPreduced-50,000-$313K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2023

Share positions as resolved from 13F-HR 0001104659-23-091377, largest first. % of portfolio is the value over $294,203,998, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 4,839,529 shares; 2023Q2: 4,839,529 shares 4,839,529$129M44%0Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 2,518,582 shares; 2023Q2: 2,518,582 shares 2,518,582$42.9M14.58%0Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: not reported; 2023Q2: 4,285,714 shares 4,285,714$33.3M11.3%newTimeline
EQRX INCEQRX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 13,104,424 shares; 2023Q2: 13,104,424 shares 13,104,424$24.4M8.28%0
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 1,221,145 shares; 2023Q2: 1,221,145 shares 1,221,145$13.1M4.47%0Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 1,910,029 shares; 2023Q2: 1,910,029 shares 1,910,029$12.8M4.35%0Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 625,485 shares; 2023Q2: 948,659 shares 948,659$11.9M4.05%+323,174Timeline
ARVNARVINAS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 287,251 shares; 2023Q2: 287,251 shares 287,251$7.13M2.42%0Timeline
KINNATE BIOPHARMA INCKINNATE BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 2,329,480 shares; 2023Q2: 2,329,480 shares 2,329,480$7.06M2.4%0
THESEUS PHARMACEUTICALS INCTHESEUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 611,310 shares; 2023Q2: 611,310 shares 611,310$5.7M1.94%0
PMVPPMV PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 521,284 shares; 2023Q2: 471,284 shares 471,284$2.95M1%-50,000Timeline
KRONOS BIO INCKRONOS BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 1,451,537 shares; 2023Q2: 1,451,537 shares 1,451,537$2.5M0.85%0
CCCCC4 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 375,857 shares; 2023Q2: 375,857 shares 375,857$1.03M0.35%0Timeline

How Q2 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-23-091377 base2023-08-14acceptance time not in the bulk data set